Analysed IMMUTEP LTD-SP ADR (IMMP:NASDAQ) News Sources
Immutep Announces Abstract Accepted for Presentation at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
22-04-2026
yahoo.com
Systemic immune activation with eftilagimod alfa associated with statistically significant increased overall survival in late-stage cancer patients
28-05-2026
yahoo.com
Immutep to Present Positive Interim Phase I Data for IMP761, a First-in-Class LAG-3 Agonist Antibody, at EULAR 2026
04-06-2026
yahoo.com
Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004
13-07-2026
yahoo.com
Immutep Secures Fourth United States Patent for Eftilagimod Alfa in Combination with a PD-1 Pathway Inhibitor
14-07-2026
yahoo.com
Correction: Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight
21-07-2026
yahoo.com
Immutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026
24-07-2026
yahoo.com
What is the current price of IMMUTEP LTD-SP ADR (IMMP:NASDAQ)?
The current price of IMMUTEP LTD-SP ADR (IMMP:NASDAQ) is $0.3819.
IMMUTEP LTD-SP ADR (IMMP:NASDAQ) absolute price change since previous trading day?
The absolute price change of IMMUTEP LTD-SP ADR (IMMP:NASDAQ) since the previous trading day is $-0.0041.
IMMUTEP LTD-SP ADR (IMMP:NASDAQ) percentage price change since previous trading day?
The percentage price change of IMMUTEP LTD-SP ADR (IMMP:NASDAQ) since the previous trading day is -1.0622%.
What is the most recent average sentiment score for IMMUTEP LTD-SP ADR (IMMP:NASDAQ)?
The most recent average sentiment score for IMMUTEP LTD-SP ADR (IMMP:NASDAQ) is 64 out of 100.
What is the most recent average sentiment for IMMUTEP LTD-SP ADR (IMMP:NASDAQ)?
The most recent sentiment for IMMUTEP LTD-SP ADR (IMMP:NASDAQ) is .
SEC-8K** Filing Available For IMMUTEP LTD-SP ADR (IMMP:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.